ImmunoGen, Inc. Announces Presentations at Upcoming AACR-NCI-EORTC Anticancer Conference
-
First clinical data to be reported for
SAR566658 , further expanding the extensive body of data reported with ImmunoGen's maytansinoid antibody-drug conjugate (ADC) technology. - Presentations on new ADC technologies, including a new class of payload agents, highlight ImmunoGen's continuing leadership in advancing this high potential field.
The first clinical data with
Poster Presentations
On
-
"A phase I first-in-human study of
SAR566658 , an anti-CA-6-antibody-drug conjugate in patients with CA6-positive advanced solid tumors" (Poster Session A, Abstract #A73).
On
- "New Class of DNA-alkylating agents with a suitable tolerability profile created for use in antibody-drug conjugates (ADCs)" (Poster Session C, Abstract #C160).
- "Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models" (Poster Session C, Abstract #C162).
- "New tri-glycl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs)" (Poster Session C, Abstract #C164).
About
Kadcyla® is a registered trademark of
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products
and new anticancer technologies. A review of these risks can be found in
ImmunoGen's Annual Report on Form 10-K for the fiscal year ended
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
The
Yates Network
Source:
News Provided by Acquire Media